FDA Lifts Age Restrictions on ARS Pharma’s Neffy Epinephrine Nasal Spray
Event summary
- FDA approves removal of age requirement for neffy 1 mg, allowing use in children weighing ≥33 lbs. regardless of age.
- Updated labeling recommends storage in blister packaging or neffy carrying case, which will be included with each prescription starting this summer.
- Approximately 25% of children under four years old who require epinephrine now have access to a needle-free treatment option.
- Additional label updates include more flexible guidance around sniffing, temperature excursions, and freezing.
The big picture
The FDA’s approval to remove age restrictions on neffy 1 mg expands access to a needle-free epinephrine treatment for younger children, addressing a significant unmet need in allergic reaction management. This move aligns with broader industry trends toward patient-centric drug formulations and could set a precedent for other epinephrine delivery systems. ARS Pharma’s strategic focus on broadening neffy’s applicability positions it to capture a larger share of the $2 billion global epinephrine market.
What we're watching
- Market Penetration
- How the removal of age restrictions will affect adoption rates among younger patients and their caregivers.
- Competitive Dynamics
- Whether ARS Pharma can sustain market share against traditional epinephrine auto-injectors with this labeling update.
- Regulatory Compliance
- The pace at which ARS Pharma can implement the new labeling and carrying case inclusion without supply chain disruptions.
Related topics